Every year, tens of thousands receive new organs. Kidneys top the list. Livers follow close. Success rates impress. But lifelong drugs shadow every victory. Immunosuppressants ward off rejection. They also invite infections, cancers, diabetes. Side effects mount over decades. What if recipients could ditch those pills? A fresh trial from Pittsburgh points that way. Three patients stayed drug-free for three years after liver transplants. No rejection. Stable health.
Researchers at the University of Pittsburgh Medical Center led the charge. They infused donor-derived regulatory dendritic cells one week before surgery. These cells act as teachers. They signal the recipient’s immune system: this liver is friend, not foe. The phase I/IIa study enrolled 16 living-donor pairs. Thirteen completed analysis. All tolerated the infusion. No serious reactions tied to cells. After one year, protocol biopsies cleared eight for weaning. Four stopped all drugs. Three held firm—off immunosuppressants for an average 3.0 years, as detailed in the April 17 Nature Communications paper. Success among weanable patients: 37.5%. Double the usual 13-16% without therapy, though small numbers limit stats.
Abhinav Humar, chief of transplantation at UPMC and first author, calls it progress. “While we haven’t hit a home run yet, we’ve definitely gotten on base by reliably and safely removing immunosuppression early after transplantation from a significant percentage of patients, which is a huge breakthrough,” he told Gizmodo on April 18. The team grew cells from donor monocytes via leukapheresis. GMP-grade. Infused at 5.2 million per kg. Standard drugs followed surgery: tacrolimus, mycophenolate, steroids tapered fast. Weaning started post-biopsy. Liver function held steady. Infections hit five patients—expected in transplants. One death: head trauma, unrelated.
And it’s not just livers. Kidneys see similar pushes. A phase 3 trial hit 75% success. HLA-matched siblings donated kidneys plus MDR-101 cells after conditioning. Nineteen of 20 tapered off all drugs by year one. Fifteen stayed free past two years. No graft losses. No donor antibodies. Better life quality, per the American Journal of Transplantation report from 2025. D.B. Kaufman directed that multicenter effort.
UCLA pushes boundaries further. Their tolerance program uses donor stem cells post-transplant—even years later. Karina Ledesma got her sister Rosa’s kidney in 2023. Drugs wrecked her sleep, nerves burned. September 2024: stem cell infusion. Now off meds. One of three fully weaned in their phase 1/2 trial of six. Three more taper low. Jeffrey Veale snagged $6.7 million from California’s regenerative institute to expand. From siblings to mismatches. Outpatient procedure. Cells engraft bone marrow. Chimerism forms. Immune system learns self from other, as UCLA Newsroom detailed November 24, 2025.
But challenges persist. Donor-specific antibodies popped in five Pittsburgh patients. Two end biopsies showed C4d staining—rejection hint. One weaned patient resumed drugs post-vaccination. Small cohorts everywhere. Phase I/IIa in Pittsburgh. No controls. Historical benchmarks only. Larger randomized trials loom. UPMC plans comparisons to standard care. Cell dose tweaks. Timing shifts.
History adds context. Livers tolerate better than others. Natural operational tolerance strikes 13% eligible adults sans intervention. Kidneys? Rarer. Half fail in 15 years on drugs. Stem cell combos shine in matches—Mayo hit 75% off meds over two years in phase 3, per 2025 reports. Northwestern engineers donor cells to fool immunity. Ongoing. University of Louisville tests mismatched pairs.
Costs factor in. Drugs run $30,000 yearly per patient. Monitoring adds up. Freedom means savings. Fewer clinic visits. Lower cancer risk. But manufacturing cells? Pricey now. Scale needed. Regulators watch. FDA eyes biomarkers like iBox for faster kidney trials.
So where next? Broader donors. Heart, lung, pancreas. Pediatric wins exist—Stanford freed kids from drugs via donor immune transplants. Pig islets test encapsulation sans suppression. Momentum builds. Three Pittsburgh patients live proof. Off pills. On with life.
Trials multiply. Pittsburgh’s NCT03164265 wrapped recruitment years back. Follow-up continues. UCLA eyes 20-year-old grafts. Tolerance holds even sans detectable donor cells—biomarkers incoming. Industry notes. UPMC Enterprises funded the dendritic push since 2017.
Rejection’s grip loosens. Slowly. Surely. Patients wait.
WebProNews is an iEntry Publication